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Iclaprim is a bacterial dihydrofolate reductase inhibitor in Phase 3 clinical development for the treatment of acute bacterial skin
and skin structure infections and hospital-acquired bacterial pneumonia caused by Gram-positive bacteria. Daptomycin,
linezolid, and vancomycin are commonly used antibiotics for these indications. With increased selective pressure to these
antibiotics, outbreaks of bacterial resistance to these antibiotics have been reported. .is in vitro pilot study evaluated the activity
of iclaprim against methicillin-resistant Staphylococcus aureus (MRSA) isolates, which were also not susceptible to daptomycin,
linezolid, or vancomycin. Iclaprim had an MIC≤ 1 µg/ml to the majority of MRSA isolates that were nonsusceptible to dap-
tomycin (5 of 7 (71.4%)), linezolid (26 of 26 (100%)), or vancomycin (19 of 28 (66.7%)). In the analysis of time-kill curves, iclaprim
demonstrated≥ 3 log10 reduction in CFU/mL at 4–8 hours for tested strains and isolates nonsusceptible to daptomycin, linezolid,
or vancomycin. Together, these data support the use of iclaprim in serious infections caused by MRSA nonsusceptible to
daptomycin, linezolid, or vancomycin.
1. Background
Iclaprim represents a diaminopyrimidine that inhibits bac-
terial dihydrofolate reductase of Gram-positive pathogens [1,
2]. Iclaprim exhibits potent in vitro activity against Gram-
positive pathogens associated with acute bacterial skin and
skin structure infections (ABSSSIs) and nosocomial pneu-
monia including Staphylococcus aureus, Enterococcus spp., and
Streptococcus spp. [1]. Iclaprim demonstrates rapid in vitro
bactericidal activity in time-kill studies in human plasma [3].
Iclaprim is in Phase 3 clinical development for the treatment of
ABSSSI and nosocomial pneumonia. Daptomycin, linezolid,
and vancomycin are commonly used antibiotics for these
indications (daptomycin is indicated for ABSSSI but not in-
dicated for nosocomial pneumonia); however, increased se-
lective pressure to these antibiotics has resulted in outbreaks of
bacterial resistance to these antibiotics. Because of this
emerging resistance, this current study was done to evaluate
iclaprim’s activity against MRSA isolates that were non-
susceptible to daptomycin, linezolid, or vancomycin.
2. Materials and Methods
Antibacterial susceptibility testing was conducted at the De-
partment of Bacteriology, Glasgow Royal InIrmary, Glasgow,
Scotland [4], and EuroIns Microbiology Laboratories on
a range of MSSA and MRSA strains and isolates with varying
susceptibilities to several recognized antistaphylococcal anti-
biotics. A total of 61 nonduplicative, nonconsecutive isolates of
methicillin-resistant S. aureus (MRSA), which were non-
susceptible to daptomycin, linezolid, or vancomycin, were
obtained from EuroIns repository or from the National
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Institutes of Health Network on Antimicrobial Resistance to
Staphylococcus aureus (NARSA) repository.
Clinical isolates were identiIed by the submitting labora-
tories, and identiIcations were conIrmed centrally at EuroIns
using the Bruker matrix-assisted laser desorption ionization-
time of Jight mass spectrometry (MALDI-TOF) biotyper.
Susceptibility testing and minimal inhibitory concentration
(MIC) interpretations were performed according to broth
microdilution protocols. S. aureus breakpoints for dapto-
mycin, linezolid, and vancomycin are ≤1, ≤4, and ≤2µg/mL
(4–8µg/mL were classiIed as vancomycin-intermediate S.
aureus and ≥16 were classiIed as vancomycin-resistant S.
aureus), respectively. To date, there are no published clinical
breakpoints for iclaprim. However, based on a number of
factors (e.g., MRSA distribution of MICs, assessment of the
pharmacokinetics/pharmacodynamics of iclaprim, and the
study of the clinical outcomes of MRSA infections when
iclaprim was used in Phase 2 and 3 studies) outlined in the
CLSIM23 guideline, an iclaprimMIC≤ 1 µg/mL for S. aureus,
including MRSA, has been proposed.
MRSA isolates were tested in cation-adjusted Mueller–
Hinton broth (CA-MHB). Quality control and in-
terpretation of results were performed in accordance with
CLSI M100-S25 methods [5]. QC ranges for iclaprim were
those approved by CLSI and published in M100-S25 [4].
Iclaprim and comparator antibiotic MIC results were within
the CLSI published ranges against S. aureus ATCC 29213.
Isolates were tested with MIC panels (.ermo Fisher Sci-
entiIc, Cleveland, Ohio, USA) of comparator antibiotics
(trimethoprim, trimethoprim-sulfamethoxazole, ceftriax-
one, erythromycin, levoJoxacin, oxacillin, meropenem, tetra-
cycline, tigecycline, vancomycin, linezolid, and daptomycin).
.e analysis of time-kill curves was performed by ex-
posing 105-106 CFU/mL of each MRSA isolate or strain to
iclaprim, daptomycin, linezolid, or vancomycin at 2, 4, and
8x MICs. Bactericidal activity was deIned as a ≥ 3 log10
reduction in CFU/mL after 24 hours of incubation.
3. Results
.e MIC50 and MIC90 values for the MRSA nonsusceptible
to daptomycin, nonsusceptible to linezolid, vancomycin-
intermediate, and vancomycin-resistant were >1/>1, 8/>8,
4/8, and >32/>32 µg/mL, respectively. Among the seven
MRSA isolates nonsusceptible to daptomycin (all seven had
an MIC> 1 to daptomycin), four, two, and one had a van-
comycin MIC of 4, 8, and 2 µg/mL, respectively.
Table 1 shows that iclaprim exhibited potent activity
against the majority of the 61 MRSA isolates that were
nonsusceptible to daptomycin, linezolid, or vancomycin
(MIC50 0.25µg/mL). In the Glasgow study, all strains and
isolates of MRSA and MSSA had an iclaprim MIC≤ 1µg/mL.
Iclaprim notably exhibited 100% activity against MRSA isolates
(n 26) that were nonsusceptible to linezolid. A total of 9
(15.2%) isolates had reduced susceptibility to iclaprim with
MICs> 8µg/mL (Table 1). .ese isolates were not clustered in
time of isolate collection, infection type, and/or geographic
region. Figure 1 shows representative time-kill curves of
iclaprim (2x, 4x, and 8x MICs for all antibiotics), which
exhibited bactericidal activity at 4–8 hours against MRSA
strains and isolates nonsusceptible to daptomycin, linezolid, or
vancomycin. As expected, representative time-kill curves of
daptomycin exhibited no activity against MRSA strains and
isolates nonsusceptible to daptomycin, linezolid exhibited no
activity against MRSA strains and isolates nonsusceptible to
linezolid, and vancomycin exhibited no activity against MRSA
strains and isolates nonsusceptible to vancomycin.
4. Discussion
.is report shows that iclaprim, without a synergistic
combination of a sulfonamide, was highly active and
rapidly bactericidal against a collection of 61 MRSA clinical
isolates with nonsusceptible phenotypes to daptomycin,
linezolid, or vancomycin. .e MIC50 value of 0.25 µg/mL
for MRSA documented in this study was consistent with
MIC50 values in two previous surveillance reports for 5937
Gram-positive isolates, including MRSA, beta-hemolytic
streptococci (most commonly Streptococcus pyogenes and
S. agalactiae), and S. pneumoniae [1]. .ese isolates were
collected from patients in the US and EU with skin and soft
tissue, blood stream, and respiratory clinical specimens.
Based on MIC distributions of MRSA, assessment of the
pharmacokinetics and pharmacodynamics of iclaprim, and the
study of the clinical outcomes of MRSA infections when
iclaprim was used in Phase 2 and 3 studies, an iclaprim
MIC≤ 1µg/mL for S. aureus, including MRSA, has been
proposed as the breakpoint for nonsusceptibility. .e 80mg
Ixed dose is based on prior animal models of infection studies,
which suggest that the pharmacokinetic and pharmacody-
namics (PK/PD) drivers, which best correlated with eMcacy,
were the area under the curve from 0 to 24 hours at steady state
(AUC0–24h,ss), AUC/minimum inhibitory concentration
(MIC), and time above the MIC during the dosing interval
(T>MIC). In addition, using PK data collected from 470
patients from a Phase 3-complicated skin and skin infection
(cSSSI) trials (ASSIST-1 and 2), population PK modeling,
and Monte Carlo simulation identiIed that the Ixed
iclaprim 80mg dosage regimen optimally maximized
AUC0–24 h,ss, AUC/MIC, and T>MIC while minimizing
Table 1: Iclaprim in vitro activity against MRSA isolates nonsusceptible to daptomycin, linezolid, or vancomycin.
MRSA phenotype (number) Iclaprim MIC≤ 1, µg/mL (%) Iclaprim MIC50/MIC90 (µg/mL) MIC range (µg/ml)
Daptomycin nonsusceptible (n 7) 5/7 (71.4) 0.25/>8 0.12–>8
Linezolid nonsusceptible (n 26) 26/26 (100.0) 0.06/0.25 0.03–1
Vancomycin intermediate (n 23) 16/23 (69.6) 0.25/>8 0.25–>8
Vancomycin resistant (n 5) 3/5 (60.0) 0.5/>8 0.25–>8
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Figure 1: Iclaprim time-kill curves against MRSA isolates nonsusceptible to linezolid, resistant to vancomycin, and nonsusceptible to dap-
tomycin, 2x, 4x, and 8x MICs were used for all antibiotics. (a) MRSA, linezolid nonsusceptible strain (MIC≥ 8µg/mL), ATCC 986537, NRS271.
(A) 2x MIC. (B) 4x MIC. (C) 8x MIC. Iclaprim showed signicantly lower CFU at 2h, 4 h, 8 h, and 24h compared to control, vancomycin, and
linezolid (P< 0.01; one-way ANOVA with Tukey’s post hoc test). (b) MRSA, vancomycin-resistant strain (MIC≥ 32µg/mL), ATCC 1409053,
vanA positive. (A) 2x MIC. (B) 4x MIC. (C) 8x MIC. Iclaprim showed signicantly lower CFU at 4h, 8 h, and 24h compared to control,
vancomycin, and linezolid (P< 0.01; one-way ANOVA with Tukey’s post hoc test). (c) MRSA, daptomycin-resistant strain (MIC≥ 4µg/mL)
(clinical isolate). (A) 2x MICs. (B) 4x MIC. (C) 8x MIC. Iclaprim showed signicantly lower CFU at 4h, 8 h, and 24h compared to control,
daptomycin, and linezolid (P< 0.01; one-way ANOVA with Tukey’s post hoc test).
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the probability of a Cmax,ss to ≥ 800 ng/mL, a concentration
associated with dose-limiting toxicity [6]. Based on PK/PD
analyses, iclaprim 80mg administered over two hours every
12 hours adequately covers S. aureus clinical isolates with an
iclaprim MIC≤ 1 µg/mL; therefore, this dose was selected as
the dosing scheme for ongoing Phase 3 clinical trials.
A limitation of this study is the small numbers of dap-
tomycin and linezolid nonsusceptible and vancomycin-
resistant MRSA strains to arrive at conclusive activity of
iclaprim against these types of strains and dose selection
justiIcation for clinical trials, which robust in vitro data are
necessary. However, these data suggest that larger studies are
warranted in examining iclaprim’s activity against dapto-
mycin and linezolid nonsusceptible and vancomycin-resistant
MRSA..e Indings of reduced daptomycin susceptibility and
reduced vancomycin susceptibility and resistance have been
reported in S. aureus. Daptomycin and vancomycin cross-
resistance is believed to be related to the physical barrier of
a thickened cell wall of MRSA against the penetration of
daptomycin and vancomycin molecules [7, 8]. A possible
reason as to why iclaprim had reduced activity against such
isolates may relate to the mechanism of action of iclaprim,
which interferes with folate metabolism in the bacterial cell by
competitively blocking the biosynthesis of tetrahydrofolate.
.is product acts as a carrier of one-carbon fragments and is
necessary for the ultimate synthesis of DNA, RNA, and
bacterial cell wall proteins. As vancomycin-resistant strains
are already altered in terms of cell wall targets, it is likely that
some products of folate metabolism are less important [9].
.e results of this in vitro study suggest that iclaprim
may be a useful treatment option for infections caused by
MRSA, including those with nonsusceptible phenotypes to
daptomycin, linezolid, or vancomycin. Daptomycin, line-
zolid, and vancomycin are antibiotics that are FDA ap-
proved, and the Infectious Diseases Society of America
guidelines list these antibiotics as treatment options for skin
and skin structure infections (SSSIs) caused by Gram-
positive pathogens [10]. New therapeutic options are needed,
especially because of reported nonsusceptibility of Gram-
positive bacteria to daptomycin, linezolid, and vancomycin
and its associated poor outcomes, increased length of stay,
healthcare costs, and overall morbidity [11–14].
5. Conclusion
In conclusion, the results from this pilot in vitro study show
the potent and rapid bactericidal activity of iclaprim against
clinical MRSA isolates, including those with nonsusceptible
phenotypes to daptomycin, linezolid, or vancomycin. Con-
tinued surveillance is warranted to track the continued po-
tency of iclaprim, as well as MRSA isolates nonsusceptible to
daptomycin, linezolid, and vancomycin and to detect any
potential emergence of resistance.
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